Your session is about to expire
What is Stivarga
RegorafenibThe Generic name of this drug
Treatment SummaryRegorafenib is a pill used to treat metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and liver cancer. It was approved by the FDA in 2012 and later in 2017 it was approved to treat liver cancer as well. Regorafenib works by blocking certain proteins in the body that are involved in tumor growth.
Stivargais the brand name
Stivarga Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Stivarga
Regorafenib
2012
1
Approved as Treatment by the FDA
Regorafenib, also called Stivarga, is approved by the FDA for 5 uses which include unresectable Gastrointestinal stromal tumor and Metastatic Gastrointestinal Stromal Tumor .unresectable Gastrointestinal stromal tumor
Metastatic Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumors
Advance Directives
Gastrointestinal Stromal Tumors
Effectiveness
How Stivarga works in the bodyRegorafenib is a drug that works by blocking the activity of certain proteins in the body. These proteins are involved in normal cell functions, but can also cause cancer, create new blood vessels to feed tumors, and help maintain the environment in which a tumor grows. In lab tests, regorafenib has been shown to stop these proteins from working, and in animal models, it has been seen to reduce tumor growth and spread.
When to interrupt dosage
The endorsed dose of Stivarga is contingent upon the diagnosed ailment, such as oxaliplatin, previously treated with anti-VEGF and unresectable Gastrointestinal stromal tumor. The magnitude of dosage is contingent upon the approach of administration (e.g. Tablet or Tablet, film coated - Oral) specified in the table beneath.Condition
Dosage
Administration
Gastrointestinal Stromal Tumors
40.0 mg,
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Advance Directives
40.0 mg,
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Liver Cancer
40.0 mg,
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
oxaliplatin
40.0 mg,
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
sorafenib
40.0 mg,
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Gastrointestinal Stromal Tumors
40.0 mg,
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
RAS wild-type with previous of anti-EGFR therapy
40.0 mg,
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
previously treated with anti-VEGF
40.0 mg,
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Colorectal Cancer
40.0 mg,
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Warnings
There are 20 known major drug interactions with Stivarga.Common Stivarga Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Regorafenib.
Axitinib
Major
The serum concentration of Axitinib can be increased when it is combined with Regorafenib.
Belinostat
Major
The metabolism of Belinostat can be decreased when combined with Regorafenib.
Bendamustine
Major
The serum concentration of Bendamustine can be increased when it is combined with Regorafenib.
Binimetinib
Major
The serum concentration of Binimetinib can be increased when it is combined with Regorafenib.
Stivarga Toxicity & Overdose RiskThe most common side effects of taking this drug are exhaustion/tiredness, difficulty speaking, diarrhea, loss of appetite, high blood pressure, mouth ulcers, throat pain, pain elsewhere in the body, weight loss, stomach or abdominal pain, rash, fever, and nausea.
Stivarga Novel Uses: Which Conditions Have a Clinical Trial Featuring Stivarga?
177 active trials are currently being conducted to investigate the potential of Stivarga to ameliorate RAS wild-type with previous history of anti-EGFR therapy, Liver Cancer and Metastatic Gastrointestinal Stromal Tumors.Condition
Clinical Trials
Trial Phases
Liver Cancer
10 Actively Recruiting
Phase 2, Phase 4, Early Phase 1, Phase 1
sorafenib
0 Actively Recruiting
Gastrointestinal Stromal Tumors
0 Actively Recruiting
previously treated with anti-VEGF
0 Actively Recruiting
RAS wild-type with previous of anti-EGFR therapy
0 Actively Recruiting
Colorectal Cancer
45 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable
Advance Directives
0 Actively Recruiting
Gastrointestinal Stromal Tumors
0 Actively Recruiting
oxaliplatin
0 Actively Recruiting
Stivarga Reviews: What are patients saying about Stivarga?
5Patient Review
1/28/2013 So far, so good. The scans have been positive and I'm responding well to the medication. I get sick if I take more than the prescribed dosage, so I stick to three pills. I'll be back for more scans in a few weeks.
5Patient Review
9/26/2018 I've been on this medication for over a year and a half now, trying Lonsurf first but seeing only minimal results. This treatment has much fewer side effects than chemotherapy (which I never ended up doing), though there is some fatigue and foot pain. Despite that, it's kept my CEA levels low.
3.7Patient Review
5/21/2017 I have a needle phobia, so many cancer treatments are out of the question for me. This oral medication is much easier to take, and I've only been on it for two weeks. So far the most notable side effects are fatigue and some mild soreness in my hands and feet, but those could improve with time or may be unrelated to the drug entirely.
3.7Patient Review
8/14/2015 I'm on my third cycle of this treatment, and I've noticed that my CEA numbers have increased.
1.7Patient Review
5/18/2016 I can't believe the FDA would approve something like this. It's torture!
Patient Q&A Section about stivarga
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is the success rate of Stivarga?
"over the course of the study.
Patients who took STIVARGA had an improved overall survival rate, living a median of 10.6 months compared to those taking placebo who only lived a median of 7.8 months. There were 233 deaths out of 379 patients with STIVARGA (62%) vs 140 deaths out of 194 patients with placebo (72%) over the course of the study."
Answered by AI
Is Stivarga chemotherapy?
"A targeted therapy is a type of cancer treatment that targets the changes in cancer cells that help them grow, divide, and spread. The trade name for the generic chemotherapy drug regorafenib is Stivarga®. In some cases, the generic name regorafenib may be used by health care professionals when referring to the trade name Stivarga®. Stivarga® is a targeted therapy; a type of cancer treatment that targets changes in cancer cells that enable their growth, division, and spread."
Answered by AI
Can Stivarga cure cancer?
"Stivarga works by inhibiting the growth of cancer cells by blocking the enzymes that promote cancer growth, including those in the vascular endothelial growth factor pathway."
Answered by AI
Is Stivarga a last resort?
"The drug regorafenib was approved last year as third line treatment for patients with advanced Gastrointestinal Stromal Tumor. Gastrointestinal stromal tumor (GIST) is a rare type of cancer found in the digestive system, most often in the wall of the stomach."
Answered by AI